Kevin Acton is currently making significant strides as a Rare Disease Specialist at Amryt Pharma plc, where he focuses on identifying and supporting patient outliers who exhibit insulin resistance, elevated triglycerides, and those who are Statin/PCSK9 non-responders. His expertise in the pharmaceutical industry, particularly in...
Kevin Acton is currently making significant strides as a Rare Disease Specialist at Amryt Pharma plc, where he focuses on identifying and supporting patient outliers who exhibit insulin resistance, elevated triglycerides, and those who are Statin/PCSK9 non-responders. His expertise in the pharmaceutical industry, particularly in rare diseases, positions him uniquely to navigate the complexities of patient care and treatment options. With Amryt Pharma’s acquisition of Aegerion Pharmaceuticals, Kevin is at the forefront of integrating innovative therapies into clinical practice, ensuring that patients receive the most effective care tailored to their unique conditions.
In his role, Kevin leverages his extensive background in pharmaceutical sales, sales operations, and hospital sales management to drive awareness and education around rare diseases. His passion for developing talent shines through in his previous roles as a Field Trainer and Manager of Learning and Development, where he honed his skills in coaching and mentoring sales teams. This experience has equipped him with a deep understanding of the nuances involved in marketing and selling complex biopharmaceutical products, particularly in the context of infectious diseases and other challenging therapeutic areas.
Kevin’s commitment to fostering a culture of continuous learning and development within his team is evident as he collaborates on key projects aimed at enhancing patient outcomes. By utilizing his strong foundation in management and marketing, he is dedicated to creating impactful strategies that not only elevate the performance of his team but also improve the lives of patients facing rare diseases. His holistic approach to sales and patient care exemplifies the critical intersection of pharmaceutical innovation and compassionate healthcare.
